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Abstract 
Background and aims: Adverse drug reactions (ADRs) can cause significant harm in patients; 
however, ADRs are under-reported in many countries, including South Africa, where evidence of a 
pharmacovigilance (PV) system to monitor and manage ADRs is a requirement for compliance with 
norms and standards for quality healthcare delivery. We conducted an analysis amongst health care 
professionals (HCPs) at Sebokeng Hospital to assess the situation there. 
Methods: Data were collected using a structured self-administered questionnaire, targeting all medical 
practitioners, nurses, pharmacists and pharmacist assistants in the hospital. Current procedures for 
reporting of ADRs were documented. Records were reviewed to determine the number of ADR 
reports submitted for the 18-month period prior to the study. Data were analysed with SAS. Ethical 
clearance was obtained. 
Results: The questionnaire was completed by 132 HCPs (nurses: 58.3%; medical practitioners: 
23.5%; pharmacist assistants: 11.4%; pharmacists: 6.8%). The vast majority indicated ADR reporting 
is necessary (96.2%) and their professional obligation (89.4%). Only 18.9% were aware of an existing 
PV system in the hospital, 15.2% had an ADR form available and 18.9% knew to whom the form 
should be submitted. The vast majority had never reported an ADR, had never received training in 
PV, but wanted training on ADR reporting. Factors discouraging ADR reporting included not knowing 
how to report them (53.8%), lack of time (37.1%), additional work load (22.0%), uncertainty about the 
outcome of reporting (32.6%), and lack of confidence to discuss ADRs with colleagues (22.0%). Only 
2.3% knew how many ADRs were reported, that ADRs are discussed by a committee (6.1%) and that 
internal feedback is received on reported ADRs (6.1%). 
Conclusion: There is an extensive need in Sebokeng Hospital for training on ADR reporting and 
implementation of systems to facilitate relevant processes; a need which may also exist in other 
public hospitals in South Africa. 
 
Key words: Pharmacovigilance, adverse drug reactions, health care professionals, hospitals, 
training, South Africa 
 
1. Introduction 
 
Adverse drug reactions (ADRs) have the potential to cause significant harm to patients (1) as they 
increase morbidity and mortality, adding to the suffering of patients (2-5). ADRs are among the 
leading causes of mortality in the USA and Europe (6-9). They have a major impact on public health 
with increased costs, exacerbated by an appreciable number of hospital admissions each year (10-
15) as well as increasing in-patient ADRs (16).  
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There is a similar situation in South Africa, with 6.3% of hospital admissions as a direct result of an 
ADR, with a further 6.3% developing an ADR whilst in hospital (1,17).  A recent cross-sectional survey 
conducted in the adult medical wards of four geographically diverse hospitals in South Africa, 
estimated that ADRs contributed to the death of 2.9% of adult medical ward admissions and 16% of 
deaths were ADR-related (5). 
 
There are concerns at the considerable extent of under-reporting of ADRs in hospitals across all 
countries (4, 12, 18-20), with some authors putting this figure as high as 80-94% (21, 22). Correcting 
for under-reporting is difficult, however, because its extent is unknown and can be very variable. 
There are a number of reasons for under-reporting including ignorance of ADR reporting systems, 
unavailability of forms, lethargy, lack of interest, indifference and complacency (4, 20). This situation 
is not helped by a lack of training on the reporting of ADRs across countries (22, 23). The lack of 
reporting is a concern, especially among sub-Saharan African countries with their high prevalence of 
infectious diseases, which coupled with the introduction of newer more complex therapies, makes the 
detection and reporting of ADRs crucial to reduce subsequent morbidity, mortality and costs (12, 24).  
 
Identifying ADRs and reporting them should EHDYLWDOSDUWRIKHDOWKFDUHSURIHVVLRQDOV¶+&3Vdaily 
practice. Spontaneous reporting systems are an efficient means of detecting and reporting drug safety 
signals (25) which are currently used in South Africa (26); however, they rely on vigilant HCPs not 
only to generate a suspicion of an ADR during their appraisal and treatment of a patient, but also to 
report it. They are though a crucial element in the worldwide practice of pharmacovigilance and form 
the core of the World Health Organization (WHO) Database (27), growing across countries including 
Africa (28).  
 
Consequently, in all countries, there is a need to study the incidence of ADRs and create awareness 
among HCPs to encourage their reporting, reducing subsequent morbidity, mortality and costs. Early 
detection, evaluation, management and monitoring of ADRs are essential to reduce harm to patients 
and improve public health (29).  
 
Pharmacovigilance (PV) is a relatively new science and in Africa and before 2000, this was not a 
priority in view of a number of reasons including poor regulation for medicines, lack of access to them, 
concerns with supply chains, lack of knowledge regarding PV as well as lack of resources to promote 
PV (28). This is changing with 35 African countries part of the WHO Programme for International Drug 
Monitoring by the end of September 2015 (28). This includes South Africa, which joined in 1992 
reporting 28,609 individual case report forms up to 2015 (28). This has been helped by the formation 
of a PV Group within the Medicines Council of South Africa (30), providing direction on ADR reporting 
in South Africa (31). This now includes regulations concerning post-marketing reporting of ADRs, with 
a directive that all serious or suspected ADRs, whether expected or unexpected, occurring in South 
Africa must be reported by the medicine licence holder or applicant to the Medicines Control Council 
within 15 days of receipt of such information (31). There are also now regional initiatives with South 
Africa promoting PV (32). 
 
In addition, in order to provide safe quality services to the citizens of South Africa, compliance with 
specific norms and standards is a legislative requirement for different categories of health 
establishments (23,33,34). They are required to have systems in place to report adverse incidents to 
a structure within the health establishment or responsible authority that monitors these events.  
Pharmaceutical services in particular are required to ensure that reactions to drugs or severe side 
effects are reported, that the patient is properly cared for, and that a clear system is in place to 
manage ADRs (23,33).  Specially designed forms are available to report ADRs to the National 
Adverse Drug Event Monitoring Centre (NADEMC) in Cape Town, although there is recognised 
under-reporting in South Africa (1, 35,36).  
 
However, the extent of reporting of ADRs following these initiatives within public sector hospitals in 
South Africa is largely unknown, although this is changing with some local initiatives (32). Limited 
literature is available on actual current reporting of ADRs within general public sector hospitals in 
South Africa including potential barriers. Most studies highlighted lack of knowledge of ADR reporting 
with a need for targeted training (35,37,38). HCPs in clinical HIV practice in a district in Kwa-Zulu 
Natal, reported high awareness of ADR reporting (75.9% to 88.0%) with estimated adverse event 
reporting rates ranging from 1.6% to 8.7% (38). Focus group discussions from an antiretroviral 
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treatment programme in the Eastern Cape revealed lack of knowledge especially amongst junior staff 
(35). In a small study amongst HCPs from three districts in the Eastern Cape Province, less than 20% 
of HCPs indicated that they report ADRs externally (39). In a recent study amongst community and 
hospital pharmacists in North-West Province, 44% indicated that they have submitted an ADR report 
in the past (37).  
 
Consequently, we undertook a study among HCPs in a public sector hospital in South Africa to 
assess their knowledge of, attitudes to and perceptions about ADR reporting. The findings would be 
used to guide similar research in other public sector hospitals, as well as to develop pertinent 
interventions to improve future reporting, if this is an identified concern. Previous studies have shown 
that suitable interventions can improve the rate of ADR reporting (19,40,41), with hospital pharmacists 
potentially playing a key role with improving reporting rates (42). 
 
2. Methods 
 
2.1 Study setting 
This study was conducted in a secondary level care hospital in Sedibeng, Gauteng Province, South 
Africa. Sebokeng Hospital is an 800-bed referral hospital with a catchment population of over 1.1 
million. 
 
2.2 Study design 
Knowledge of, attitudes to and perceptions about ADR reporting by HCPs of Sebokeng Hospital were 
evaluated in a descriptive study. 
 
2.3 Study population and sample 
The study population included all HCPs (doctors, nurses, pharmacists and pharmacist assistants) 
who were employed at Sebokeng Hospital at the time of the study. Hence convenience sampling was 
used. 
 
2.4 Study instrument 
The study instrument was a pre-designed structured questionnaire, adapted from previous studies 
(25,43), and further developed with the support of different HCPs to ensure its suitability for our 
hospital setting. The questionnaire was structured to obtain demographic information, knowledge of 
ADR reporting, attitudes to reporting, the types of ADRs and drug-induced reactions that must be 
reported, and factors perceived to influence ADR reporting. The final questionnaire contained 19 
closed-ended questions with two or more response options, of which eight questions provided space 
for an explanation of the selected response. No prioritisation was requested with any of the questions. 
One open-ended question was included on where ADR reporting forms are kept and an invitation at 
the end of the questionnaire to state any needs or suggestions in terms of ADR reporting. The 
questionnaire was completed anonymously and took approximately 7-10 minutes to complete.     
 
2.5 Data collection 
Data were collected over a period of one week in 2015. A total number (547) of medical practitioners, 
pharmacists and nurses were employed at Sebokeng Hospital at the time of the study. General 
communication to the wards was used to inform HCPs working in the hospital at the time of data 
collection of the study. Convenience sampling was used to invite the HCPs who were present in a 
particular ward at the time of data collection, to participate in the study and complete the needs 
analysis questionnaire. They were informed that participation was voluntary and were provided with 
written information about the study, explaining its aims and objectives. On their agreement to 
participate, written informed consent was obtained from them. The questionnaire was handed to 
respondents for immediate completion in a private area in the ward or pharmacy, such as an office or 
consultation room. Respondents were requested to place the questionnaire upon completion in a 
sealed container provided in the area.   
 
A retrospective review of hospital records was also conducted to determine the number of ADR 
reports submitted at Sebokeng Hospital for the 18-month period prior to the study. Current procedures 
for reporting of ADRs for patients admitted to the hospital were also documented.  
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2.6 Data analysis 
Data collected with the questionnaire were entered HOHFWURQLFDOO\RQDQ062IILFH([FHOVSUHDG
sheet, proof-read for accuracy and completeness and cleaned prior to the analysis. All statistical 
procedures were performed on SAS, release 9.2, running under Microsoft Windows. Data were 
summarised descriptively and expressed as frequencies and percentages. Responses to questions 
where an explanation was requested, were read a number of times and categories were created 
based on the responses. Responses were then tabulated according to the categories, which allowed 
for counting of the responses in each category. 
 
2.7 Ethical considerationsEthical clearance for the study was obtained from the Medunsa Research 
Ethics Committee of the University of Limpopo, now known as Sefako Makgatho Health Sciences 
University, prior to the commencement of the study (Clearance number: MREC/H/26/2014:PG). 
Ethical approval was also obtained from the Gauteng Provincial Ethics Committee. Permission to 
conduct the study was obtained from the Chief Executive Officer of the hospital. All respondents in the 
study remained anonymous and data were handled confidentially. Only the authors had access to the 
raw data, which were stored appropriately. The results of this study were subsequently made 
available to the Sebokeng Hospital Management and the Pharmacovigilance Unit of the Gauteng 
Department of Health to plan initiatives if needed to improve ADR reporting in the future. 
 
3. Results 
 
According to the review of records at the time of the study, only six ADRs were reported for the 
preceding 18 months, between January 2014 and May 2015.   
 
Although the invitation to participate in the study was extended to all 547 HCPs employed at the 
hospital via normal communication channels, only 200 HCPs who were present in the wards on the 
day of data collection, agreed to participate in the study and received the questionnaire. Of the 200 
questionnaires distributed, 132 were completed, giving a completion rate of 66% and a response rate 
of 24%. Respondents to the questionnaire consisted of 31 (24%) medical practitioners, 77 (58%) 
nurses, 15 (11%) pharmacist assistants and 9 (7%) pharmacists. Participants from all age groups 
completed the questionnaire: 21-30 years (30%), 31-40years (22%), 41-50 years (23%), 51-60years 
(20%) and more than 60 years (5%). 
 
Table 1 shows the knowledge, attitudes and practices of HCPs on ADR reporting. Only 25 (18.9%) of 
the HCPs were aware of the existing ADR reporting system and 20 (15.2%) were aware that ADR 
reporting forms were available in the ward/hospital. Only seven (5.3%) HCPs indicated that they had 
received training on ADR reporting prior to this study, whilst almost 90% (118) of HCPs indicated that 
they would like to receive training on ADR reporting.  
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Table 1: Knowledge, attitudes and practices of healthcare professionals on adverse drug reaction 
reporting at Sebokeng Hospital 
 
Adverse drug reaction 
(ADR) reporting 
Number (%) of healthcare professionals 
Medical 
Practitioner 
(n=31) 
Pharmacist 
(n=9) 
Pharmacist 
Assistant 
(n=15) 
Nurse 
(n=77) 
Total 
(n=132) 
Aware of an ADR 
reporting system in 
Sebokeng Hospital 
2 (6.5%) 8 (88.9%) 5 (33.3%) 10 (12.9%) 25 (18.9%) 
Know of an ADR reporting 
form available in the 
ward/ hospital 
4 (12.9%) 2 (22.2%) 8 (53.3%) 6 (7.8%) 20 (15.2%) 
Know to whom the 
completed ADR form 
must be submitted 
4 (12.9%) 6 (66.7%) 3 (20.0%) 12 (15.6%) 25 (18.9%) 
ADR reporting is a 
professional obligation 
31 (100%) 9 (100%) 11 (73.7%) 67 (87.0%) 118 (89.4%) 
ADR reporting should be 
voluntary 
5 (16.1%) 0 (0%) 2 (13.3%) 5 (6.5%) 12 (9.1%) 
ADR reporting should be 
remunerated 
1 (3.22%) 0 (0%) 2 (13.3%) 8 (10.4%) 11 (8.3%) 
ADR reporting should be 
compulsory 
25 (80.7%) 9 (100%) 11 (73.3%) 64 (83.1%) 109 (82.6%) 
Received training on ADR 
reporting 
0 2 (22.2%) 4 (26.7%) 1 (1.3%) 7 (5.3%) 
Would like to receive 
training on ADR reporting 
30 (96.8%) 9 (100%) 14 (93.3%) 65 (84.4%) 118 (89.4%) 
 
The vast majority (96.2%) of HCPs indicated that it was necessary to report an ADR (Figure 1A), 
however only 16 (12.1%) had ever reported one (Figure 1B). The 16 HCPs who indicated that they 
had reported an ADR in the past included four medical practitioners, five pharmacists and seven 
nurses. 
 
Figure 1A and B: Reporting of adverse drug reactions by health care professionals at Sebokeng 
hospital  
   
One of the questions was aimed at determining whether the HCPs knew to whom they should submit 
completed ADR forms. Only 25 (18.9%) HCPs (4 medical practitioners, 12 nurses; 3 pharmacist 
Do not know; 
3; 2%
No; 2; 
2%
Yes; 
127; 96%
A. Necessary to report ADRs (n=132)
No; 116; 
88%
Yes; 16; 
12%
B. Whether an ADR was reported 
previously (n=132)
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assistants; 6 pharmacists) knew that ADR reports should be sent to the pharmacy within the hospital. 
Other factors associated with under-reporting of ADRs are shown in Figure 2. They included a lack of 
time to look for ADRs in the ward (37.1%) as well as a lack of time to complete a report (37.1%), the 
µUHSRUWPD\EHZURQJ¶(34.1%) DQGµGRQRWNQRZLIDQ\WKLQJZLOOEHGRQHZLWKWKHGDWD¶ (32.6%). More 
than half (54.5%) of the HCPs indicated that they did not know how, where or when to report an ADR. 
 
Figure 2: Determinants of under-reporting of adverse drug reactions by healthcare professionals at 
Sebokeng Hospital (n=132) 
 
2WKHUTXHVWLRQVSUREHG+&3V¶SHUFHSWLRQVDERXW$'5s and spontaneous ADR reporting. Types of 
ADRs that might elicit reporting by HCPs are presented in Figure 3. Adverse reactions to a new 
medicine (91.7%) and a serious adverse event to a particular medicine (90.9%) were the ADRs that 
most needed to be reported.  
 
Figure 3: Types of adverse drug reactions that elicited reports from healthcare professionals at 
Sebokeng Hospital (n=132) 
 
The majority of HCPs (89.4%) felt that ADR reporting is a professional obligation. In terms of whose 
professional responsibility it is to report an ADR, 85.6% felt it was the responsibility of a medical 
practitioner and a nurse to report ADRs, while 72.0% felt it was the responsibility of a pharmacist (see 
Figure 4). 
22.0%
22.0%
22.7%
32.6%
34.1%
37.1%
37.1%
54.5%
0% 10% 20% 30% 40% 50% 60%
Concern that reporting may generate extra work
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Congenital anomaly
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Figure 4: Perceived professional responsibility to report an adverse drug reaction by healthcare 
professionals at Sebokeng Hospital (n=132) 
 
)LJXUHVKRZV+&3V¶SHUFHSWLRQVDERXWZKHWKHUDGYHUVHHYHQWVUHODWHGWRspecific categories of 
medicines and devices must be reported. The majority believed that it was mandatory to report 
adverse events due to vaccines (95.0%) and blood products (91.0%). 
 
Figure 5: Perceived importance to report adverse events related to various categories of medicines 
(n=132) 
 
 
4. Discussion 
 
There appeared to be serious under-reporting of ADRs within Sebokeng hospital with only six ADRs 
reported between January 2014 and May 2015. According to an ADR database kept for the 34  public 
sector hospitals in the Gauteng Province, only 41 ADRs were reported by the hospital between 2012 
and March 2017 (32). Only 44% of the 34 hospitals in the province reported any ADRs with the 
number of ADR reports submitted, ranging from one to 123 for the 5-year period. Only two hospitals 
reported more ADRs than Sebokeng hospital (secondary level of care) with 123 and 59 ADR reports 
respectively submitted for the 5-year period by a tertiary and central academic hospital. These figures 
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suggested that the number of reports submitted is not associated with the size of the hospital, nor the 
level of care provided; for example, 11, 22 and 59 reports were submitted by the three largest central 
academic hospitals, while most ADRs were reported by a tertiary level hospital (32). Similar to other 
studies, these figures are showing serious under-reporting (12, 19, 21, 22). 
 
Comparable to other studies (4, 20, 44, 45), low reporting rates may be due to the fact that the 
majority of HCPs in the hospital (81.1%) were not aware of the existing ADR reporting and monitoring 
systems as well as the process for reporting. In addition, most of them (94.7%) had not been trained 
in ADR reporting (Table 1). The fact that a higher percentage of pharmacists than other HCPs were 
DZDUHRIWKHV\VWHPPD\EHUHODWHGWRSKDUPDFLVWV¶HGXFDWLRQDERXWGUXJVDIHW\DQGWKHIDFWWKDW
ADR report forms were required to be channelled to and through the pharmacy. In addition, more 
pharmacists than other HCPs had been trained in ADR reporting (Table 1).  This lack of training and 
awareness of reporting ADRs may have been behind the fact that very few HCPs had ever reported 
an ADR (12.1%) as found in our study, despite the high number (96.2%) knowing it was necessary to 
report these when they occur (Figure 1). This figure is lower than the 22.8% of respondents in a 
hospital of Madhya Pradesh, in India (46), and may reflect the high number of HCPs in our study 
(89.4%) requesting training in ADR reporting (Table 1).  
 
This lack of knowledge is reflected by the high percentage of HCPs stating they did not know how, 
when and where to report ADRs as well as lacked confidence in their reporting (Figure 2). This was 
despite, as mentioned, the overwhelming number of the HCPs feeling that ADR reporting was 
necessary and that it is a professional obligation (89.4%). This is seen as particularly important for 
ADRs to new medicines and a serious adverse event to particular medicines (Figure 3), with the 
responsibility of reporting ADRs up to all HCPs, particularly medical practitioners and nurses (Figure 
4).  
 
In addition to not knowing how, where and when to report ADRs, the lack of time to complete an ADR 
report as well as actively look for ADRs while on the ward, coupled with concerns that the report may 
be wrong, were principal reasons for not completing one (Figure 2). These results differ from an 
Australian study where the most frequently stated barrier to reporting ADRs among medical 
practitioners and nurses was the lack of feedback (47). Encouragingly, only a limited number of HCPs 
(22.0%) were concerned that reporting may generate extra work. Although there are a number of 
studies that assess causes of under-reporting ADRs (4, 20, 40, 41, 44, 48-50), only a few have fully 
evaluated barriers in hospitals. We believe this is important, given the potential impact of ADRs in 
hospitals on morbidity, mortality and costs. Through baseline assessments and training undertaken in 
our hospital, a number of factors were identified as contributing to the poor culture of ADR reporting 
among HCPs. These included: unavailability of ADR forms in consulting; lack of awareness of the 
importance of ADR reporting; poor feedback of what happens after HCWs complete ADR forms; and 
lack of awareness of what to report. 
 
In this study, there was a general perception that ADR reporting is mostly for blood products and 
vaccines (Figure 5). The finding that only 59.1% of respondents identified allopathic drugs, i.e. the 
mainstream Western medicines, as requiring reporting is a concern (Figure 5). It implies that reporting 
of ADRs to common therapeutic medicines is currently not seen as important, except in the case of 
new medicines. Only one study was found where reporting all ADRs was regarded as more important 
than reporting only serious and unexpected reactions (51). Consequently, there appears to be a lack 
of awareness that well-recognised ADRs, when an ADR is suspected, even those not known to the 
drug or even suspected drug interactions, and related morbidity and mortality, require equal vigilance 
and prompt reporting to meet international, national and regional requirements, for marketed 
medicines (27, 28, 31, 52).  This matter needs to be addressed. 
 
Encouragingly, while some HCPs felt that ADR reporting should be voluntary (9.1%) and remunerated 
(8.3%), the majority (82.6%) felt that it should be made compulsory (Table 1), which is a standards 
requirement for quality service delivery in South Africa (23,33). 
 
To improve spontaneous reporting rates, 89.4% of our respondents indicated that they would like to 
receive appropriate training (Table 2). HCPs also need to be familiarised with the PV system in 
hospitals and trained in using it. This objective could be achieved through in-house meetings and 
training sessions. Appropriate training has been shown to improve HCPs reporting of ADRs in other 
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countries (19, 40, 41, 53, 54), with hospital pharmacists potentially playing a key role in improving 
reporting rates (42).  
 
We are now planning continuing education of HCPs about PV in our hospital through oral 
presentations, verbal reminders, increasing the accessibility of ADR report forms, and increased 
attendance of pharmacists in the wards, similar to methods described in other studies (47). The 
impact of these interventions will be measured to guide future activities in this and other public 
hospitals in South Africa. 
 
We are aware that the major limitation of this study is that it was carried out in only one public sector 
hospital in South Africa. We believe though other public sector hospitals in South Africa will show 
similar findings and are undertaking similar research in other hospitals, as well as undertaking 
educational activities in this hospital, to try to address the appreciable under-reporting of ADRs in 
South Africa and the consequences among public sector hospitals in South Africa.   
 
5. Conclusion 
 
This study provides insight into various reasons for extensive under-reporting of ADRs among public 
sector hospitals in South Africa building on previous research, highlighting the lack of knowledge and 
awareness among HCPs about PV and ADR reporting systems. Principal reasons for under-reporting 
included HCPs did not know how to report, where to report and when to report ADRs. The fact that 
most HCPs admitted that they had not previously received training on ADR reporting indicates that 
providing training would be useful to address current concerns. There are ongoing activities in our 
hospital to address critical under-reporting of ADRs and to use the findings to guide future activities in 
this and other public sector hospitals in South Africa. 
 
We hope our findings and activities will also be of interest to other public hospitals in Africa and other 
countries with similar situations to South Africa to help improve ADR reporting in general, and with it 
reduce associated morbidity, mortality and costs. 
 
Key points and what this study adds 
 
x ADRs are important causes of mortality and morbidity in both hospitalised and ambulatory 
patients adding to costs; however, they continue to be under-reported across all countries 
including South Africa. This is important as an appreciable number of ADRs can be prevented 
x Under-reporting of ADRs frustrates efforts to identify, evaluate and prevent unusual, serious, 
hazardous and novel ADRs, and thus under-estimates their burden in populations 
x The lack of knowledge about ADR reporting amongst HCPs in South Africa and across countries 
remains a problem, adding to the extent of under-reporting including South Africa where reports 
remain low 
x Training on PV should be continuous among HCPs across sectors to identify potential ADRs and 
deal with them to improve future care 
x The importance of PV has not been emphasized enough in the training of HCPs across countries, 
which needs to be addressed. This includes raising the importance of reporting ADRs which is 
sub-optimal even in countries where such reporting is mandatory 
x Barriers to ADR reporting should be identified and reduced through activities such as education, 
monitoring and feedback 
x Staff shortage remain a barrier because if there are not enough staff, there will not be enough 
time to complete the forms. This needs to be addressed since recognising and reporting ADRs 
will reduce mortality and costs in the long term saving, with beds available to treat other patients 
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